Residual γh2AX foci predict local tumour control after radiotherapy

Radiotherapy and Oncology

Volumn 108, Issue 3, 2013, Pages 434-439

  Koch, Ulrike ^a,b   Höhne, Katharina ^b   Von Neubeck, Cläre ^a,b   Thames, Howard D ^c   Yaromina, Ala ^b,d   Dahm Daphi, Jochen ^e   Baumann, Michael ^a,b,f   Krause, Mechthild ^a,b,f  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY OF TEXAS   (United States)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e Helmholtz Center Dresden Rossendorf ^*  (Germany)

^f INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Biomarker; DNA repair; gamma; H2AX; Local tumour control; Radiotherapy; Tumour micromilieu

Indexed keywords

GAMMA HISTONE H2AX; HISTONE H2AX; UNCLASSIFIED DRUG;

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IRRADIATION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION EXPOSURE; TUMOR BLOOD FLOW; TUMOR XENOGRAFT;

BIOMARKER; DNA REPAIR; LOCAL TUMOUR CONTROL; RADIOTHERAPY; TUMOUR MICROMILIEU; ΓH2AX;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HISTONES; HUMANS; MICE;

EID: 84887020226     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.06.022     Document Type: Article

References (39)

1. M. Soliman, A. Yaromina, and S. Appold GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial Radiother Oncol 106 2013 299 304
2. H.D. Suit, M. Baumann, S. Skates, and K. Convery Clinical interest in determinations of cellular radiation sensitivity Int J Radiat Biol 56 1989 725 737
3. C.M. West, M.J. McKay, and T. Holscher Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting Int J Radiat Oncol Biol Phys 62 2005 1264 1273
4. A. Yaromina, M. Krause, and M. Baumann Individualization of cancer treatment from radiotherapy perspective Mol Oncol 6 2012 211 221
5. T. Helleday, J. Lo, D.C. van Gent, and B.P. Engelward DNA double-strand break repair: from mechanistic understanding to cancer treatment DNA Repair (Amst) 6 2007 923 935
6. K. Rothkamm, I. Kruger, L.H. Thompson, and M. Lobrich Pathways of DNA double-strand break repair during the mammalian cell cycle Mol Cell Biol 23 2003 5706 5715
7. R.G. Bristow, H. Ozcelik, F. Jalali, N. Chan, and D. Vesprini Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies Radiother Oncol 83 2007 220 230
8. E.P. Rogakou, D.R. Pilch, A.H. Orr, V.S. Ivanova, and W.M. Bonner DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J Biol Chem 273 1998 5858 5868
9. E.P. Rogakou, C. Boon, C. Redon, and W.M. Bonner Megabase chromatin domains involved in DNA double-strand breaks in vivo J Cell Biol 146 1999 905 916
10. A. Kinner, W. Wu, C. Staudt, and G. Iliakis Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin Nucleic Acids Res 36 2008 5678 5694
11. W.M. Bonner, C.E. Redon, and J.S. Dickey GammaH2AX and cancer Nat Rev Cancer 8 2008 957 967
12. K.J. McManus, and M.J. Hendzel ATM-dependent DNA damage-independent mitotic phosphorylation of H2AX in normally growing mammalian cells Mol Biol Cell 16 2005 5013 5025
13. E. Soutoglou, and T. Misteli Activation of the cellular DNA damage response in the absence of DNA lesions Science 320 2008 1507 1510
14. A. Takahashi, and T. Ohnishi Does gammaH2AX foci formation depend on the presence of DNA double strand breaks? Cancer Lett 229 2005 171 179
15. J.P. Banath, S.H. Macphail, and P.L. Olive Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines Cancer Res 64 2004 7144 7149
16. J.P. Banath, and P.L. Olive Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks Cancer Res 63 2003 4347 4350
17. S.H. MacPhail, J.P. Banath, T.Y. Yu, E.H. Chu, H. Lambur, and P.L. Olive Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays Int J Radiat Biol 79 2003 351 358
18. S.H. MacPhail, J.P. Banath, Y. Yu, E. Chu, and P.L. Olive Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-phase cells Radiat Res 159 2003 759 767
19. R. Mirzayans, D. Severin, and D. Murray Relationship between DNA double-strand break rejoining and cell survival after exposure to ionizing radiation in human fibroblast strains with differing ATM/p53 status: implications for evaluation of clinical radiosensitivity Int J Radiat Oncol Biol Phys 66 2006 1498 1505
20. P.L. Olive, and J.P. Banath Phosphorylation of histone H2AX as a measure of radiosensitivity Int J Radiat Oncol Biol Phys 58 2004 331 335
21. C.A. Banuelos, J.P. Banath, J.Y. Kim, C. Aquino-Parsons, and P.L. Olive GammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation Clin Cancer Res 15 2009 3344 3353
22. P.L. Olive, and J.P. Banath Kinetics of H2AX phosphorylation after exposure to cisplatin Cytomet B Clin Cytom 76 2009 79 90
23. P.L. Olive, J.P. Banath, and L.T. Sinnott Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3-amino-1,2,4-benzotriazine-1,3-dioxide Cancer Res 64 2004 5363 5369
24. A. Menegakis, A. Yaromina, and W. Eicheler Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining Int J Radiat Biol 85 2009 1032 1041
25. A. Menegakis, W. Eicheler, A. Yaromina, H.D. Thames, M. Krause, and M. Baumann Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours Radiother Oncol 100 2011 137 144
26. P.L. Olive, C.A. Banuelos, R.E. Durand, J.Y. Kim, and C. Aquino-Parsons Endogenous and radiation-induced expression of gammaH2AX in biopsies from patients treated for carcinoma of the uterine cervix Radiother Oncol 94 2010 82 89
27. A. Yaromina, H. Thames, and X. Zhou Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation Radiother Oncol 96 2010 116 122
28. A. Yaromina, D. Zips, and H.D. Thames Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies Radiother Oncol 81 2006 122 129
29. A. Yaromina, M. Krause, and H. Thames Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation Radiother Oncol 83 2007 304 310
30. M. Baumann, W. Dubois, and H.D. Suit Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units Radiat Res 123 1990 325 330
31. U. Kasten-Pisula, A. Menegakis, and I. Brammer The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair Radiother Oncol 90 2009 257 264
32. H.L. Janssen, A.S. Ljungkvist, and P.F. Rijken Thymidine analogues to assess microperfusion in human tumors Int J Radiat Oncol Biol Phys 62 2005 1169 1175
33. L.M. Cobb, J. Nolan, and S.A. Butler Distribution of pimonidazole and RSU 1069 in tumour and normal tissues Br J Cancer 62 1990 915 918
34. C. Rosenberger, C. Solovan, and A.D. Rosenberger Upregulation of hypoxia-inducible factors in normal and psoriatic skin J Invest Dermatol 127 2007 2445 2452
35. A. Yaromina, T. Holscher, and W. Eicheler Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma? Radiother Oncol 76 2005 206 212
36. K. Rothkamm, and M. Lobrich Evidence for a lack of DNA double-strand break repair in human cells exposed to very low X-ray doses Proc Natl Acad Sci U S A 100 2003 5057 5062
37. M. Baumann, M. Krause, H. Thames, K. Trott, and D. Zips Cancer stem cells and radiotherapy Int J Radiat Biol 85 2009 391 402
38. W.Y. Mansour, N.V. Bogdanova, and U. Kasten-Pisula Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma Radiother Oncol 106 2013 147 154
39. R. Mehra, K.K. Ang, and B. Burtness Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer Semin Radiat Oncol 22 2012 194 197